Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay

Journal of Steroid Biochemistry and Molecular Biology

Volumn 110, Issue 1-2, 2008, Pages 39-47

  McRobb, L ^a,b   Handelsman, D J ^b   Kazlauskas, R ^c   Wilkinson, S ^d   McLeod, M D ^d   Heather, A K ^a,b  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NATIONAL MEASUREMENT INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Androgen; Androgen receptor; Hormone; Progesterone receptor; Progestin; Sports doping; Steroid

Indexed keywords

18 METHYL 19 NORTESTOSTERONE; 19 NORPROGESTERONE DERIVATIVE; ALTRENOGEST; ANDROGEN RECEPTOR; CHLORMADINONE; CYPROTERONE; CYPROTERONE ACETATE; DELMADINONE ACETATE; ETHISTERONE; ETHYLESTRENOL; GESTAGEN; GESTRINONE; HYDROXYFLUTAMIDE; HYDROXYPROGESTERONE; METRIBOLONE; MIFEPRISTONE; NANDROLONE; NANDROLONE DERIVATIVE; NILUTAMIDE; NORBOLETONE; NORETHANDROLONE; NORETHISTERONE; NORGESTREL; PROGESTERONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; TESTOSTERONE DERIVATIVE; TETRAHYDROGESTRINONE; TRENBOLONE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG MARKETING; DRUG SCREENING; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; NONHUMAN; RISK ASSESSMENT; STEROID ANALYSIS; STRUCTURE ACTIVITY RELATION; YEAST;

ANDROGENS; BIOLOGICAL ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHISTERONE; GESTRINONE; MOLECULAR STRUCTURE; NORETHINDRONE; NORGESTREL; NORPREGNENES; NORPROGESTERONES; PROGESTINS; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; STRUCTURE-ACTIVITY RELATIONSHIP; YEASTS;

EID: 44349161271     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.10.008     Document Type: Article

References (47)

1. Kondro W. Athletes' "designer steroid" leads to widening scandal. Lancet 362 9394 (2003) 1466
2. Catlin D.H., Sekera M.H., Ahrens B.D., Starcevic B., Chang Y.C., and Hatton C.K. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun. Mass Spectrom. 18 12 (2004) 1245-1249
3. Death A.K., McGrath K.C.Y., Kazlauskas R., and Handelsman D.J. Tetrahydrogestrinone (THG) is a potent androgen and progestin. J. Clin. Endocrinol. Metab. 89 5 (2004) 2498-2500
4. Labrie F., Luu-The V., Calvo E., Martel C., Cloutier J., Gauthier S., Belleau P., Morissette J., Levesque M.H., and Labrie C. Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J. Endocrinol. 184 2 (2005) 427-433
5. Sekera M.H., Ahrens B.D., Chang Y.C., Starcevic B., Georgakopoulos C., and Catlin D.H. Another designer steroid: discovery, synthesis, and detection of 'madol' in urine. Rapid Commun. Mass Spectrom. 19 6 (2005) 781-784
6. Catlin D.H., Ahrens B.D., and Kucherova Y. Detection of norbolethone, an anabolic steroid never marketed, in athletes' urine. Rapid Commun. Mass Spectrom. 16 13 (2002) 1273-1275
7. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W., and Thijssen J.H. Classification and pharmacology of progestins. Maturitas 46 Suppl. 1 (2003) S7-S16
8. Djerassi C., Miramontes L., Rosenkranz G., Sondheimer F., and Steroids L.I.V. Synthesis of 19-nor-17alpha-ethynyltestosterone and 19-nor-17alpha-methyltestosterone. J. Am. Chem. Soc. 76 (1954) 4092-4094
9. Rowlands S. Newer progestogens. J. Fam. Plann. Reprod. Health Care 29 1 (2003) 13-16
10. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 240 4854 (1988) 889-895
11. Brinkmann A.O., Faber P.W., van Rooij H.C., Kuiper G.G., Ris C., Klaassen P., van der Korput J.A., Voorhorst M.M., van Laar J.H., Mulder E., et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J. Steroid Biochem. 34 1-6 (1989) 307-310
12. Brinkmann A.O., and Trapman J. Genetic analysis of androgen receptors in development and disease. Adv. Pharmacol. 47 (2000) 317-341
13. WADA, The World Anti-Doping Code-the 2007 Prohibited List, www.wada-ama.org/rtecontent/document/2007_List_En.pdf, 2007 (accessed May 5, 2007).
14. Sakiz E., and Azadian-Boulanger G. R2323-an original contraceptive compound. Excerpta Med. 219 (1971) 865-971
15. Gaido K.W., Leonard L.S., Lovell S., Gould J.C., Babai D., Portier C.J., and McDonnell D.P. Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol. Appl. Pharmacol. 143 1 (1997) 205-212
16. Roy P., Franks S., Read M., and Huhtaniemi I.T. Determination of androgen bioactivity in human serum samples using a recombinant cell based in vitro bioassay. J. Steroid Biochem. Mol. Biol. 101 1 (2006) 68-77
17. Arnold S.F., Robinson M.K., Notides A.C., Guillette Jr. L.J., and McLachlan J.A. A yeast estrogen screen for examining the relative exposure of cells to natural and xenoestrogens. Environ. Health Perspect. 104 5 (1996) 544-548
18. Bovee T.F., Helsdingen R.J., Koks P.D., Kuiper H.A., Hoogenboom R.L., and Keijer J. Development of a rapid yeast estrogen bioassay, based on the expression of green fluorescent protein. Gene 325 (2004) 187-200
19. Fang H., Tong W., Branham W.S., Moland C.L., Dial S.L., Hong H., Xie Q., Perkins R., Owens W., and Sheehan D.M. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem. Res. Toxicol. 16 10 (2003) 1338-1358
20. Death A.K., McGrath K.C., and Handelsman D.J. Valproate is an anti-androgen and anti-progestin. Steroids 70 14 (2005) 946-953
21. Metzger D., White J.H., and Chambon P. The human oestrogen receptor functions in yeast. Nature 334 6177 (1988) 31-36
22. McGuire J.L., Bariso C.D., and Shroff A.P. Interaction between steroids and a uterine progestogen specific binding macromolecule. Biochemistry 13 2 (1974) 319-322
23. Smith H.E., Smith R.G., Toft D.O., Neergaard J.R., Burrows E.P., and O'Malley B.W. Binding of steroids to progesterone receptor proteins in chick oviduct and human uterus. J. Biol. Chem. 249 18 (1974) 5924-5932
24. Raudrant D., and Rabe T. Progestogens with antiandrogenic properties. Drugs 63 5 (2003) 463-492
25. Foster R.H., and Wilde M.I. Dienogest. Drugs 56 5 (1998) 825-835
26. Sitruk-Ware R., and Spitz I.M. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception 68 6 (2003) 409-420
27. Delettre J., Mornon J.P., Ojasoo T., and Raynaud J.P. An approach to the mapping of the steroid hormone receptor. In: Bresciani F. (Ed). Perspectives in Steroid Receptor Research (1980), Raven Press, New York 1-21
28. Poujol N., Wurtz J.M., Tahiri B., Lumbroso S., Nicolas J.C., Moras D., and Sultan C. Specific recognition of androgens by their nuclear receptor. A structure-function study. J. Biol. Chem. 275 31 (2000) 24022-24031
29. Ojasoo T., and Raynaud J.P. Unique steroid congeners for receptor studies. Cancer Res. 38 11 (1978) 4186-4198
30. Raynaud J.P., Bouton M.M., Moguilewsky M., Ojasoo T., Philibert D., Beck G., Labrie F., and Mornon J.P. Steroid hormone receptors and pharmacology. J. Steroid Biochem. 12 (1980) 143-157
31. Shinohara Y., and Baba S. Stable isotope methodology in the pharmacokinetic studies of androgenic steroids in humans. Steroids 55 4 (1990) 170-176
32. Quincey R.V., and Gray C.H. The metabolism of [1,2-3H]17-alpha-methyltestosterone in human subjects. J. Endocrinol. 37 1 (1967) 37-55
33. Ishak K.G., and Zimmerman H.J. Hepatotoxic effects of the anabolic/androgenic steroids. Semin. Liver Dis. 7 3 (1987) 230-236
34. Cabasso A. Peliosis hepatis in a young adult bodybuilder. Med. Sci. Sports Exerc. 26 1 (1994) 2-4
35. Petera V., Bobek K., and Lahn V. Serum transaminase (GOT, GPT) and lactic dehydrogenase activity during treatment with methyl testosterone. Clin. Chim. Acta 7 (1962) 604-606
36. Redmer D.A., and Day B.N. Ovarian activity and hormonal patterns in gilts fed allyl trenbolone. J. Anim. Sci. 53 4 (1981) 1088-1094
37. Hodgson D., Howe S., Jeffcott L., Reid S., Mellor D., and Higgins A. Effect of prolonged use of altrenogest on behaviour in mares. Vet. J. 169 3 (2005) 322-325
38. Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., Otto N., Joschko S., Scholz P., Wegg A., Basler S., Schafer M., Egner U., and Carrondo M.A. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275 34 (2000) 26164-26171
39. Bourguet W., Germain P., and Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21 10 (2000) 381-388
40. Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., Wu G.Y., Scheffler J.E., Salvati M.E., Krystek Jr. S.R., Weinmann R., and Einspahr H.M. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 98 9 (2001) 4904-4909
41. Marhefka C.A., Moore II B.M., Bishop T.C., Kirkovsky L., Mukherjee A., Dalton J.T., and Miller D.D. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J. Med. Chem. 44 11 (2001) 1729-1740
42. Sitruk-Ware R. New progestagens for contraceptive use. Hum. Reprod. Update 12 2 (2006) 169-178
43. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 47 4 (2004) 277-283
44. Phillips A., Hahn D.W., Klimek S., and McGuire J.L. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 36 2 (1987) 181-192
45. Beresford N., Routledge E.J., Harris C.A., and Sumpter J.P. Issues arising when interpreting results from an in vitro assay for estrogenic activity. Toxicol. Appl. Pharmacol. 162 1 (2000) 22-33
46. Yin D., Xu H., He Y., Kirkovsky L.I., Miller D.D., and Dalton J.T. Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J. Pharmacol. Exp. Ther. 304 3 (2003) 1323-1333
47. Stanczyk F.Z. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev. Endocr. Metab. Disord. 3 3 (2002) 211-224